tag gain-therapeutics 
Pharmaceutical Technology
SEPTEMBER 30, 2022
Spark Therapeutics’ Luxturna, indicated for inherited retinal disease (IRD), was the first gene therapy to be approved, in 2017, with a price tag of $850,000 for each eye. Gene therapies for rare inherited diseases are very expensive, as they tend to be the only therapeutic option available to patients and are often curative.
Rethinking Clinical Trials
APRIL 18, 2023
This broad set of clinical conditions and varied underlying causes underscore the need for testing a broad portfolio of therapeutic agents. RECOVER is a patient-centered, integrated, adaptive research network. It seems the most severely affected people came from the early waves of COVID.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
APRIL 13, 2023
Released on April 12, the report focuses on bluebird bio’s lovotibeglogene autotemcel and Vertex Pharmaceuticals and CRISPR Therapeutics’ exagamglogene autotemcel or exa-cel and their potential use in treating sickle cell disease. million to achieve $150,000 per QALY gained from a healthcare system perspective.
Pharmaceutical Technology
JUNE 29, 2022
For example, while orphan drug designations have more than doubled in the last decade compared to the previous one, only 16% of therapies with orphan tags have managed to gain FDA approval in some indications. The total number of designations more than doubled during 2010–21 compared to those given in the preceding decade.
Pharmaceutical Technology
FEBRUARY 10, 2023
This is not the first treatment to come with a high price tag. 52% of RSAs focus on oncology RSAs are predominantly arranged within oncology (52%) since these drugs typically rely on RSAs to gain reimbursement. million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.
pharmaphorum
OCTOBER 21, 2021
Vounatsos also insisted that Aduhelm’s price tag has not been a factor discouraging treatment with the drug. billion, with Tecfidera’s decline offset in part by gains for follow-up drug Vumerity (diroximel fumarate), which brought in $121 million. That dragged down Biogen’s overall revenues, which fell 18% to $2.2
pharmaphorum
JANUARY 21, 2022
The Oslo Medicines Initiative (OMI), which held its first public webinar event last week, was conceived before the pandemic, but it has gained new relevance as it seeks to address this disparity in Europe, a union of countries with hugely varying income levels. Finding solutions.
Expert insights. Personalized for you.
289 
Let's personalize your content